Melanóma: vizsgálatok itt: Németország
48 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- No phaseTaking peopleReducing Symptom Burden Through Physical Exercise in Melanoma Patients
- Where
- Essen
- Életkor
- 18 év and over
- People
- 86
- Run by
- Universität Duisburg-Essen
See details and how to joinNCT06985056 - 1/2. fázisTaking peopleA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- Muenster, Tuebingen
- Életkor
- 6 hónap to 17 év
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00 - 3. fázisTaking peopleAdjuvant Tebentafusp in High Risk Ocular Melanoma
- Where
- Berlin, Essen, Hamburg, Heidelberg
- Életkor
- 18 év and over
- People
- 290 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT06246149 · EU 2023-510333-28-00 - 1/2. fázisTaking peopleACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Where
- Berlin, Bonn, Dresden, Hamburg, Heidelberg, Mainz, Munich, Würzburg
- Életkor
- 18 év and over
- People
- 375 worldwide
- Run by
- Immatics US, Inc.
See details and how to joinNCT03686124 - 3. fázisTaking peopleNeoadjuvant Darovasertib in Primary Uveal Melanoma
- Where
- Berlin, Bonn, Dessau-Rosslau, Erlangen, Essen, Luebeck, Marburg, Muenster, Tuebingen, Ulm, Wuerzburg
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07015190 · EU 2025-522387-32-00 - No phaseTaking peoplePhysical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma
- Where
- Hamburg
- People
- 40
- Run by
- Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT07564570 - 1/2. fázisTaking peopleA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- Where
- Bonn, Erlangen, Essen, Hamburg, Heilbronn
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06413680 · EU 2025-523399-22-00 - 2/3. fázisTaking peopleDICIT: Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastatic melanoma patients. A single arm phase II trial
- Where
- Essen, Halle (Saale), Mainz, Regensburg
- Életkor
- 18 év and over
- People
- 48
- Run by
- Universitaetsklinikum Regensburg
See details and how to join2023-504191-26-00 · EU 2023-504191-26-00 - 2/3. fázisTaking peopleA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Where
- Berlin, Hamburg, Heidelberg
- Életkor
- 18 év and over
- People
- 280 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06581406 · EU 2023-508784-68-00 - 3. fázisTaking peopleTebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Where
- Berlin, Cologne, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Kiel, Minden, Munich, Tuebingen
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Immunocore Ltd
See details and how to joinNCT05549297 · EU 2022-502732-39-00 - 3. fázisTaking peopleIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Where
- Berlin, Bremen, Dortmund, Dresden, Erfurt, Erlangen, Essen, Frankfurt, Giessen, Hamburg, Heidelberg, Kiel, Leipzig, Mainz, Marburg, Minden, Munich, Tübingen, Würzburg
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Immunocore Ltd
See details and how to joinNCT06112314 - 4. fázisTaking peopleA Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
- Where
- Heidelberg, Munich
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06887348 · EU 2025-521621-33-00 - No phaseTaking peopleUrolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
- Where
- Frankfurt
- Életkor
- 18 év and over
- People
- 45
- Run by
- Goethe University
See details and how to joinNCT07161310 - 3. fázisTaking peopleEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- Where
- Augsburg, Berlin, Dresden, Essen, Freiburg im Breisgau, Heidelberg, Kiel, Leipzig, Tuebingen
- Életkor
- 18 év and over
- People
- 186 worldwide
- Run by
- Philogen S.p.A.
See details and how to joinNCT03567889 · EU 2023-507119-36-00 - No phaseNot yet taking people in NémetországNeutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
- Where
- Heidelberg
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- OncoHost Ltd.
See details and how to joinNCT07246759 - No phaseTaking peopleVideo-Tumorboard PLUS
- Where
- Bonn, Dresden, Münster
- Életkor
- 18 év and over
- People
- 300
- Run by
- University Hospital Muenster
See details and how to joinNCT06980740 - No phaseTaking peopleObservational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.
- Where
- Heidelberg, München, Tübingen
- Életkor
- 18 év and over
- People
- 196
- Run by
- Pamgene International B.V.
See details and how to joinNCT06784778 - No phaseTaking peopleThe Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.
- Where
- Dresden
- Életkor
- 18 év and over
- People
- 3000
- Run by
- Technische Universität Dresden
See details and how to joinNCT06765850 - 1/2. fázisTaking peopleIntradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
- Where
- Tuebingen
- Életkor
- 18 év and over
- People
- 96 worldwide
- Run by
- The Netherlands Cancer Institute
See details and how to joinNCT06240143 · EU 2023-505945-19-00 - No phaseTaking peopleArtificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults
- Where
- Tübingen
- People
- 3000 worldwide
- Run by
- German Cancer Research Center
See details and how to joinNCT06621810 - No phaseTaking peopleStereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Where
- Hamburg
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04498767 - 2. fázisTaking peoplePhase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Where
- Essen, Heidelberg
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- IO Biotech
See details and how to joinNCT05280314 - No phaseTaking peopleBinimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
- Where
- Ahaus, Aschaffenburg, Augsburg, Berlin, Bremerhaven, Buxtehude, Chemnitz, Donauwörth, Dresden, Duisburg, Erfurt, Essen, Gera, Giessen, Goslar, Göttingen, Hamburg, Hanover, Heidelberg, Karlsruhe, Kiel, Landshut, Leipzig, Lübeck, Ludwigshafen, Magdeburg, Mainz, Mannheim, Marburg, Minden, München, Münster, Nuremberg, Regensburg, Schorndorf, Schwerin, Stolberg, Trier, Tübingen, Zwickau
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Pierre Fabre Pharma GmbH
See details and how to joinNCT04045691